MacroGenics (NASDAQ:MGNX – Get Free Report) and ImmuCell (NASDAQ:ICCC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.
Profitability
This table compares MacroGenics and ImmuCell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MacroGenics | -59.46% | -98.30% | -30.28% |
| ImmuCell | -3.76% | -3.52% | -2.26% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for MacroGenics and ImmuCell, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MacroGenics | 1 | 5 | 2 | 0 | 2.13 |
| ImmuCell | 0 | 1 | 0 | 0 | 2.00 |
Volatility & Risk
MacroGenics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.
Insider and Institutional Ownership
96.9% of MacroGenics shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 13.0% of MacroGenics shares are held by company insiders. Comparatively, 5.6% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares MacroGenics and ImmuCell”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MacroGenics | $149.96 million | 1.45 | -$66.97 million | ($1.20) | -2.86 |
| ImmuCell | $27.64 million | 2.17 | -$1.04 million | ($0.11) | -60.27 |
ImmuCell has lower revenue, but higher earnings than MacroGenics. ImmuCell is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.
Summary
MacroGenics beats ImmuCell on 8 of the 14 factors compared between the two stocks.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.
